Oncology Breakthroughs and Beyond: the ASCO 2023 Impact
As we approach the 2023 ASCO Annual Meeting, we can't help but feel excited about the abundance of ground-breaking research and advancements in oncology that will be showcased. Every year, ASCO serves as a pivotal platform for oncology professionals to come together, share knowledge and drive the future of cancer care. At Real Chemistry, we recognize the importance of staying at the forefront of the latest advances and are committed to providing our clients and the broader healthcare community with valuable insights and support.
At our core, we believe in the synergy of human intelligence and artificial intelligence to create transformative solutions for the healthcare industry. Fostering an environment where innovative ideas can thrive and approaching every challenge with curiosity and collaboration, our team is eager to immerse ourselves in ASCO 2023, learning from experts and engaging in thought-provoking discussions.
Join us as we navigate this exciting landscape together, exploring the latest trends in oncology, capturing insights from our team members, and discovering how Real Chemistry’s unique ethos can support your needs in this ever-evolving field.
Revolutionizing Cancer Care with AI Technology
AI has captured headlines as of late, already revolutionizing many industries, and oncology is no different. During the past several years, we have seen the application of AI in oncology with a particular focus on diagnostics and screening. Early detection and accurate diagnosis of disease remain critical factors in improving patient outcomes. AI has demonstrated the potential to aid in both areas – for example, by improving the efficiency and accuracy of mammogram interpretation or helping detect malignant cells on pathology samples to diagnose cancer early. AI and machine learning are also the engine behind multi-cancer early detection (MCED) tests, which aim to enhance early cancer detection by detecting the presence and origin of cancer markers within a simple blood sample.
But the role of AI in pathology hasn't been limited just to primary diagnosis. Its role in identifying patient subpopulations, determining biomarker status, and predicting response to targeted therapies is rapidly changing the way pathologists approach their entire workflow. Advances in technology and an increased focus on precision medicine have made possible the development of novel digital pathology-based assessments, empowering pathologists to detect information beyond human visual perception.
The role of digital pathology is gaining traction at ASCO 2023, with a number of posters and plenaries discussing the role of image analysis to inform clinical decision-making. Beyond academia, pharmaceutical companies have begun to incorporate novel computational-based biomarkers into prospective clinical trials, accelerating AI into mainstream diagnostics and solidifying its long-term role in the pathologist’s tool kit.
The widespread adoption of AI as a crucial tool in diagnostics and screening is evident from discussions among physicians on social media. Real Chemistry Integrated Intelligence (I2) team's social listening research revealed that, over the past three years, radiologists and pathologists have been the major contributors (36% and 34%, respectively) to HCP conversations about AI's role in oncology. They have surpassed other specialists such as oncologists (13%), who usually play a more significant role in treating cancer.
With sessions at ASCO 2023 focusing on “Using AI to Optimize Drug Combinations and Dosing” and “A Machine Learning Framework to Improve Treatment Selection,” it’s evident that AI is being applied to address challenges in the treatment of cancer, such as improving drug development and predicting response to therapy. Prediction of the efficacy of immune checkpoint inhibitors has been a particular area of need, as biomarkers that can accurately identify patients likely to respond to cancer immunotherapy are lacking. At this year's ASCO, we're seeing more research focusing on novel patterns of immune cells, or immune signatures, within the tumor to identify patients with a higher likelihood of achieving benefit with this class of treatment. The new developments are essentially using AI as a tool to supercharge the field’s pursuit of personalized medicine, a long-standing goal in oncology for the past two decades.
AI has the potential to revolutionize cancer care, from improving diagnosis and screening to developing personalized treatments based on a patient's unique genetic makeup, but it is only beginning to scratch the surface. As with any new technology, there are challenges to be addressed, such as ensuring the quality and accuracy of data used to train AI models and ensuring the privacy and security of patient data. Despite these challenges, the potential benefits of AI in cancer care make it a promising area for continued research and development.
Novel Therapeutics in Oncology
One of the intriguing developments in the field of oncology is the emergence of next-generation Antibody-Drug Conjugates (ADCs). These are an innovative technology that represents a promising leap forward in cancer treatments, offering a more targeted approach to destroying cancer cells by harnessing the specificity of monoclonal antibodies and the potency of cytotoxic drugs to directly target and kill cancer cells while sparing healthy tissues. This targeted therapy approach minimizes the systemic toxicity typically associated with chemotherapy.
The latest advances in ADCs have focused on improving their stability and reducing off-target effects. Enhancements in linker technology, which connect the monoclonal antibody to the cytotoxic drug, have been key to these improvements. More stable linkers reduce the risk of premature drug release, thereby minimizing side effects and maximizing the drug's impact on cancer cells.
Moreover, there's an increased exploration in utilizing ADCs for solid tumors, such as breast cancer. Ongoing research and clinical trials have demonstrated positive results, broadening the potential application of ADCs in oncology. With several ADCs already approved to treat breast cancer and more in various stages of clinical trials, these ground-breaking treatments are benefitting more patients than ever before. We are seeing promising results across multiple settings, including in patients with heavily pre-treated and hard-to-treat cancers.
We recognize the transformative potential of advancements such as ADCs in reshaping oncology. Simultaneously, we appreciate the challenges oncologists face, including time constraints and the need to constantly update their knowledge in this rapidly evolving field. To that end, we are dedicated to creating engaging and tailored educational content that helps them stay up-to-date on the latest developments. Our commitment extends beyond understanding these breakthroughs. We aim to contextualize them in meaningful ways for our pharma clients and the broader medical community. Through fostering insightful dialogues, offering robust medical affairs support, and devising data-driven strategies, we strive to enhance scientific communication that will drive improvements in patient outcomes.
Conclusion
As we anticipate the transformative discussions at ASCO 2023, it's evident that the oncology field continues to advance rapidly, from the increasing role of AI in diagnostics and treatment to the promising progress of next-generation ADCs. At Real Chemistry, we are committed to leveraging these developments, providing actionable insights through AI, supporting medical affairs strategies, and driving medical education initiatives that keep healthcare professionals at the forefront of knowledge. We invite you to connect with us to discuss these developments, share your thoughts, or explore how we can support your needs in this exciting field. Together, we can contribute meaningfully to improving patient outcomes in oncology.
To discuss how we can support your work to improve patient outcomes in oncology, please reach out to our team at abrooks@realchemistry.com (Medical Communications/Affairs) or jwels@realchemistry.com (Medical Insights & Impact). If you will be at ASCO 2023 in Chicago, we can set up a meeting.
